Type 1A Diabetes (Immune Mediated)
-
Upload
many87 -
Category
Health & Medicine
-
view
947 -
download
2
description
Transcript of Type 1A Diabetes (Immune Mediated)
Type 1A Diabetes(Immune Mediated)
Clinical Immunology SocietyGeorge S. Eisenbarth
Barbara Davis Center for Childhood Diabetes
Slides Chosen From Teaching Slides of:Type 1 Diabetes: Molecular, Cellular, Clinical
Immunology-www.barbaradaviscenter.org
Made possible through an unrestricted educational grant from KRONUS.
WWW.BARBARADAVISCENTER.ORG: Book: Immunology Type 1 Diabetes Teaching slides are Powerpoint slide sets that can be downloaded.1. Primer Immunology and Autoimmunity (Updated - 12/03)
Stephanie C. Eisenbarth2A. Cell Therapy of Diabetes (Updated - 3/02)Jan Nygaard Jensen and Jan Jensen2B. Proprotein Processing and Pancreatic Islet Function (Updated - 3/02)John Hutton, Tina Wasmeier, Rodabe Amaria, Nicholas Bright and John Creemers 2C. Stimulus-Secretion Coupling in the Pancreatic Beta-Cell (Updated - 3/02)Kirstine Juhl and John Hutton 3. Animal Models of Type 1 Diabetes: Genetics and Immunological Function (Updated - 8/02)Julie Lang and Donald Bellgrau4. The Role of T Cells in Beta Cell Damage in NOD Mice and Humans (Updated - 3/02)Katalin Kelemen5. Type 1 Diabetes Mellitus: An Inflammatory Disease Of The Islet (Updated - 12/03)Regine Bergholdt, Peter Heding, Karin Nielsen, Runa Nolsøe, Thomas Sparre, Joachim Størling,
2. Allan E. Karlsen, Jørn Nerup, Flemming Pociot and Thomas Mandrup-Poulsen. Steno Diabetes 3. Center, Gentofte, Denmark
6. The Immunobiology of Pancreatic Islet Transplantation (Updated - 11/01)Marilyne Coulombe and Ronald G. Gill7. Type I Diabetes Mellitus of Man: Genetic Susceptibility and Resistance (Updated - 4/02) A. Pugliese and G. S. Eisenbarth8. Autoimmune Polyendocrine Syndromes (Updated - 10/03)J.M. Barker and G. S. Eisenbarth9. Epidemiology of Type I Diabetes (Updated - 4/02)Marian Rewers, Jill Norris and Dana Dabelea10. Humoral Autoimmunity (Updated - 9/02) L. Yu and G.S. Eisenbarth11. Prediction of Type I Diabetes: The Natural History of the Prediabetic Period (Updated - 11/03)George S. Eisenbarth12. Clinical Trials for the Prevention of Type I Diabetes (Updated - 9/03)H. Peter Chase, Anthony R. Hayward & G. S. Eisenbarth
1986 NEJM “Stages” in Development of Type1Diabetes
Age (years)
Genetic Predisposition
Bet
a ce
ll m
ass
(?Precipitating Event)
Overtimmunologicabnormalities
Normal insulinrelease
Progressiveloss insulinrelease
Glucosenormal
Overtdiabetes
C-peptidepresent
NoC-peptide
Pea
k in
sulin
res
po
nse
to
intr
aven
ou
s g
luco
se
(1+
3 m
in)
imm
un
ore
acti
ve in
sulin
(μ
U/m
l)
0
50
100
150
200
250
300
350
'66 '67 '68 '69 '70 '71 '72 '73 '74 '75'66 '68 '70 '72 '74 '76 '78 '80 '82
ANTIBODY NEGATIVE
*
**
ANTIBODY POSITIVE
*
DM
Srikanta S. et al, New Engl J Med 308:322-325, 1983
Triplets Serial Intravenous Glucose Tolerance Tests
Stages Type IA Diabetes
•I Genetic Susceptibility• II Triggering• III Active Autoimmunity• IV Progressive Metabolic
Abnormalities• V Overt Diabetes• VI Insulin Dependence
Type 1A DiabetesType 1A Diabetes
• Monogenic:Monogenic: Single gene defect.Single gene defect. APS-I: AIRE autosomal recessive APS-I: AIRE autosomal recessive XPID: Scurfy Gene X-linked XPID: Scurfy Gene X-linked
• Polygenic:Polygenic: Summation of small effects of Summation of small effects of multiple genes creating diabetes multiple genes creating diabetes susceptibility (e.g. NOD mouse)susceptibility (e.g. NOD mouse)
• Oligogenic:Oligogenic: MHC+few major genesMHC+few major genes Genetic heterogeneity with Genetic heterogeneity with
different major non-MHC genes different major non-MHC genes for for different families (e.g. BB rat)different families (e.g. BB rat)
BDC
Human Leukocyte Antigen
human MHC
cell-surface proteins
important in self vs. nonself distinction
present peptide antigens to T cells
CLASS I: A,B,C CLASS II: DR,DQ,DP
HLAJ. Noble
The Major Histocompatibility Complex
Human
Mouse
DP DQ DR B C A
K I-A I-E D L
Chromosome 6
Chromosome 17
Class II Class III Class I
Class II Class III Class IClass I
Complement Proteins
Cytokines Class I-like genesand pseduogenes
Antigen Processing Genes
TERMINOLOGY
DRB1*02
DQB1*0302DRB1*0401
DRB1*0401
DRB1*0301
DQB1*0302
DRB1*0401
DQB1*02(DQ2)
Allele:
Haplotype:
Genotype
J. Noble
DR4
DR3
DR4
DR4
DQ2
DQ8
DQ8
DQB1*0402
Asp57
Leu56
-chain
-chain
BDC BDC
0
1
2
3
4
5
Od
ds r
ati
o
0
20
40
60
80
Tra
ns
mis
sio
n f
req
ue
ncy
(%)
******
**
* *
*p< 0.05 vs. control haplotype
High risk
ProtectiveModerate risk
461 389 40 51 182 82 99 20 121 55 124 27 135 34
HBDI Families: Odds Ratio
HBDI Families: Transmission from Heterozygous Parents
BDC
Insulin Gene (INS)
Class I VNTR26-63 repeats
21 alleles
Predisposing
IDDM2
Insulin Gene (INS)
Class III VNTR140-200 repeats
15 alleles
IDDM2
Protective
The IDDM2 Locus
VNTR = Variable Number of Tandem Repeats
Inherited Susceptibility Loci
LOCUS CHROMOSOME CANDIDATE GENES or MICROSATELLITES
IDDM1 6p21 HLA-DQ\DR
IDDM2 11p15 INS VNTR
IDDM3 15q26 D15s107
IDDM4 11q13 MDU1, ZFM1, RT6, FADD/MORT1, LRP5
IDDM5 6q24-27 ESR, MnSOD
IDDM6 18q12-q21 D18s487, D18s64, JK (Kidd locus)
IDDM7 2q31 D2s152, IL-1, NEUROD, GALNT3
IDDM8 6q25-27 D6s264, D6s446, D6s281
IDDM9 3q21-25 D3s1303
IDDM10 10p11-q11 D10s193, D10s208, D10s588
IDDM11 14q24.3-q31 D14s67
IDDM12 2q33 CTLA-4, CD28
IDDM13 2q34 D2s137, D2s164, IGFBP2, IGFBP5
IDDM14 ? NCBI # 3413
IDDM15 6q21 D6s283, D6s434, D6s1580
IDDM16 ? NCBI # 3415
IDDM17 10q25 D10s1750-D10s1773
OTHERS
Autoimmune Polyendocrine Syndromes• APS-II (Autoimm Polyendocrine)
• APS-I (AIRE mutation)
• XPID: (Scurfy Mutation)
• Anti-insulin Receptor Abs + “Lupus”
• Hirata (Anti-insulin Autoantibodies)
• POEMS (Plasmacytoma,..)
• Thymic Tumors + Autoimmunity
• Congenital Rubella + DM +Thyroid
APS-SyndromesBetterle et al. Endocrine Reviews 23:327-364Neufeld and Blizzard: 1980, Pinchera, in Symposium
Autoimmune Endocrine Aspects of Endocrine Disorders
• APS-I:>=2 of Candidiasis, Hypopara,Addison’s
• APS-II:Addison’s + Autoimmune Thyroid and/or Type 1 Diabetes
• APS-III: Thyroid Autoimmune + other autoimmune [not above]
• APS-IV: Two or more organ-specific autoimmune, not I,II, or III.
General Paradigm
• Identify Genetic Susceptibility
• Detect Initial Autoantibodies
• Monitor Metabolic Decompensation
• Treat Overt Disease Prior to
Morbidity/Mortality
• Basic/Clinical Research to Allow Prevention
Associated Autoimmune IllnessesCeliac Disease: Diarrhea, weight loss, growth
failure, abdominal pain, osteoprorosis, anemia
Hyperthyroid: Hypothyroid:
Weight loss, feeling warm, anxiety, bulging eyes Weight gain, feeling cold
Pernicious Anemia: Anemia, movement problems
Addison’s Disease: Darkening of skin, loss of weight, dizziness, nausea
Ovarian Failure: Premature menopause, hot flashes, infertility
Myasthenia Gravis: Muscle weakness, double vision
Diabetes Mellitus: Increased urination, thirst, appetite, weight loss, coma
Comparison APS-I and APS-II APS-I APS-II
• Onset Infancy• Siblings
AIRE gene mutated• Not HLA Associated• Immunodeficiency
AsplenismMucocutaneous Candidiasis
• 18% Type 1 DM
• Older Onset• Multiple Generations• DR3/4 Associated• No Defined
Immunodeficiency• 20% Type 1 DM
BDC
APS-I• Autoimmune Polyendocrine Syndrome Type
1• Autosomal Recessive mutations AIRE
(Autoimmune Regulator) gene• Mucocutaneous Candidiasis/Addison’s
Disease/Hypoparathyroidism• 18% Type 1 Diabetes• “Transcription Factor” in Thymus
BDC
XPID: X-linked polyendocrinopathy, immune dysfunction and diarrhea
• Other NamesIPEX: Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linkedXLAAD: X-Linked Autoimmunity Allergic Dysregulation
• Foxp3 Gene Mutation
• Loss of Regulatory T LymphocytesBone Marrow Transplant with Chimera “Cures” Scurfy Mouse and Man
BDC
Mutations for XPID Syndrome Scurfy/Foxp3/JM2 Gene
Fork Head HomologyZn Zip
X
X
Scurfy
D
ORF
XLAAD-100
XLAAD-200
Zn = Zinc-finger domain, Zip = Zip Motif
ORF = Predicted Open Reading Frame
Modified from Review by Patel, JCI, 2000
Major DR/DQ Associations• Type 1 Diabetes
DR3: DRB1*0301/DQA1*0501/DQB1*0201DR4: DRB1*0401/DQA1*0301/DQb1*0302
• Celiac DiseaseThe same as Type 1 DM plusDR5/DR7 = DQA1*0501/DQB1*0201 in trans
• Addison’s DiseaseThe same as Type 1 DM but DRB1*0404 preference (Yu, JCEM 84:328,1999)
BDC
Known Initiators
DISEASE INITIATOR ASSOCIATIONCeliac Gliadin/wheat
glutenPredominant
InsulinAutoImmune
SH-Drugsmethimizole
Predominant
Type 1 DM Cong Rubella RareThyroiditis Iodine “Common”Graves’ Anti-CD52 RareMyasthenia Penicillamine Rare
Mediator/Autoantigen(s)
Graves’ Antibody TSH ReceptorMyasthenia Antibody ACh ReceptorInsulin Auto Antibody InsulinCeliac ? TransglutaminaseType 1 DM T Cell Insulin/GAD/
ICA512Addison’s T Cell 21-OHThyroiditis T Cell Thyroglobulin
Peroxidase
Celiac Disease
• Intestinal Autoimmune Disorder
• Anti-Transglutaminase (EMA)
• 1/200 General Population U.S./Europe1/20 Patients with Type 1 DM1/6 Patients Type 1 DM who are DR3/DR3
• Gliadin Induction
• Hypothesis: transglutaminase+gliadin
Prevalence of TGA by HLA-DR amongst patients with type 1 DM, relatives of DM patients and
general population
0%
5%
10%
15%
20%
25%
DR3+ DR3-
IDDMRelativesPopulation
Prevalence
HLA-DR
BDC
Stages Type IA Diabetes
• I Genetic Susceptibility
•II Triggering• III Active Autoimmunity• IV Progressive Metabolic
Abnormalities• V Overt Diabetes• VI Insulin Dependence
Environment
•Congenital Rubella•Controversy re Enteroviruses/
other virus•Controversy re bovine milk•Hygiene Hypothesis•2 JAMA papers re early cereal
Ziegler, JAMA 2003: 290:721
0
5
10
15
20
25
30
0 2 4 6 8
Age (years)
Isle
t au
toim
mu
nit
y, %
<=3 mo.
>6 mo.
>3 to6 mo.
DR3/4 DQ8: Norris JAMA 290:1713
0
5
10
15
20
25
0 2 4 6 8
Age (years)
Isle
t A
uto
imm
un
ity,
%
<=3 mo.
4 o 6 mo.
>=7 mo.
BabyDiab and DAISY
Age introduction gluten (Ziegler) or cereal (Norris) greatly increases development of anti-islet autoantibodies in infants followed from birth.
Stages Type IA Diabetes
• I Genetic Susceptibility• II Triggering
•III Active Autoimmunity• IV Progressive Metabolic
Abnormalities• V Overt Diabetes• VI Insulin Dependence
Insulin Autoantibodies:A Chain L13
ReceptorBindingRegion
Experimental Autoimmune Diabetes
B:9-23 Peptide ----- Insulin Autoantibodies
B:9-23 Peptide + Poly-IC ------ Insulitis
B:9-23 Peptide + Poly-IC + B7.1 Islet -- Diabetes
Moriyama et al. PNAS 99: 5539-5544, 2002
B Chain 1: FVKQHLCGPHLVEALYLVCGERGFFYTPKS 2
B Chain 2: FVKQHLCGSHLVEALYLVCGERGFFYTPMS
Difference of Amino acid sequence Difference of Amino acid sequence between preproinsulin 1 and 2between preproinsulin 1 and 2
B:9-23
Leader 1: MALLYHFLPL LALLALWEPKPTQA 6
Leader 2: MALWMRFLPL LALLFLWESHPTQA
A Chain 1: GIVDQCCTSI CSLYQLENYC N 0A Chain 2: GIVDQCCTSI CSLYQLENYC N
C-Peptide 1: EVEDPQVEQLELGGSPGDLQTLALEVARQ 5
C-Peptide 2: EVEDPQVAQLELGGGPGAGDLQTLALEVAQQ
insulin 1 KO male
0 10 20 30 40 500
20
40
60
80
100
weeks of age
% o
f d
iab
ete
s f
ree
Insulin 1 KO female
0 10 20 30 40 500
20
40
60
80
100
weeks of age
% o
f d
iab
ete
s f
ree
Insulin 2 KO male
0 10 20 30 40 500
20
40
60
80
100
weeks of age
% o
f d
iab
ete
s f
ree
Insulin 2 KO female
0 10 20 30 40 500
20
40
60
80
100
weeks of age
% o
f d
iab
ete
s f
ree
PNAS 2003,18:10376
Diabetes Autoimmunity Study in the Young Sibling/offspring cohortGeneral population cohort
enrolled = 293 high risk 72
429 moderate risk 220
347 average - low risk 401
1,069 All 693
relatives 1,491 1,007
screened = 21,713
HLA-defined IDDM risk groupsDenver population, n=9,338
IDDM risk by age 20 HLA-DR DQB1 Frequency %
High 1:15 3/4 0201/0302 2.4 Moderate 4/x 0302/ 12.7 1:60-1:200 4/4 0302/ 3.0 3/3 0201/0201 1.4
Average 1:300 3/x 0201/ 12.5 3/4 0201/not 0302 1.0
Lower than 1:300 4/x, 4/4 /not 0302 6.6 others 60.4
DAISY 7/96
Autoantibodies
•Insulin
•Glutamic Acid Decarboxylase
•ICA512 (IA-2)
IAA assay
3. Add Protein A/G-Sepharose to reaction mix in a 96-well filtration plate
High Throughput Anti-Insulin Autoantibody Assay
Sera
2. Incubate 72 hours at 4 C
4. Incubate for 45 min at 4 C
5. Wash each well using the vacuum- operated 96-well plate washer
6. Count radioactivity with 96-well plate beta counter
Ag-Ab mixture
Vacuum
o
o
(125)Insulin
Beta Counter
Protein A/G Sepharose
1. mix (125)I-insulin and sera
1
10
100
1000
10000
5 10 15 20 25 30 35
Age (years)
An
ti-i
ns
uli
n a
uto
an
tib
od
ies
(n
U/m
l)
Insulin Autoantibodies Versus Age of Diabetes Onset
Diabetes Care 11:736-739, 1988
The Levels of mIAA in Prediabetic Children
0.0001
0.001
0.01
0.1
1
10
0 2 4Age (years)
Le
ve
l of m
IAA
(ind
ex
)
0.0001
0.001
0.01
0.1
1
10
0 2 4
Age (years)
Level o
f mIA
A (in
dex)
DM
DM
DM
DM
DM
Yu et al. PNAS: 97:1701-1706, 2,000 BDC
DAISY AUTOANTIBODIES:Initial Test <Age 1
0 1 2 3 40
20
40
60
80
100
Percent with Persistent Autoantibodies (GAA/IAA/ICA512)
3/4SOC
3/4NEC
not 3/4SOC
not 3/4NEC
3/4 SOC: 15 9 5 43/4 NEC: 151 110 67 18-3/4 SOC: 69 56 39 16 3-3/4 NEC: 492 300 208 110
p<.0001
12/27/97
0
20
40
60
80
100
0 2.5 5 7.5 10 12.5 15
3 Abs2 Abs1 Ab
Progression to Diabetes vs Number of Autoantibodies(GAD, ICA512, Insulin)Percent not Diabetic
Years of Follow-up
3 Ab n = 41 17 8 1 2 Abs n = 44 27 15 4 2 11 Abs n = 93 23 14 10 6 4
Stages Type IA Diabetes
• I Genetic Susceptibility• II Triggering• III Active Autoimmunity
•IV Progressive Metabolic Abnormalities
• V Overt Diabetes• VI Insulin Dependence
We can now predict type 1 diabetes.
We cannot now prevent type 1
diabetes.
What are we missing?
Assay for Pathogenic T
cells.
? TETRAMER
? ELISPOT
MHC peptide
HLA Class II tetramer (DR0401-hGAD555-567)
Leucinezippers spacers
streptavidin
W.W.Kwok & G.T.Nepom, BenaroyaResearch Institute at Virginia Mason
Female NOD Mice Peripheral Blood
Avidin
Kd
NRP-V7 Peptide (KYNKANVFL)
Kd
Kd
Kd
Tetramer Analysis
0
0.2
0.4
0.6
0.8
1
1.2
5 10 14 18 21 24 27 30
Age (weeks)% t
etra
mer
+ C
D8+
cel
ls
Diabetes
0
0.2
0.4
0.6
0.8
1
1.2
5 9 12 15 18 21 24 27 30
Age (weeks)% t
etra
mer
+ C
D8+
cel
ls
No Diabetes
Trudeau,Santamaria,Tan: JCI 2003
IGRP-2nd Beta Cell Specific Ag
Multiple Trials New Onset Planned/
Underway•Anti-CD3 Monoclonal•Anti-IL2 Receptor + MMF•Altered Peptide Ligand B:9-23
insulin•HSP 60, p277 Peptide (LADA
Pts)•GAD65 (LADA patients)
Changes from Study Entry to 12 Months in the Total C-Peptide Response to Mixed-Meal Tolerance Testing
Herold K. et al., N Engl J Med 2002; 346:1692-8.
To
tal
Are
a u
nd
er t
he
C-P
epti
de
Res
po
nse
Cu
rve
(nm
ol/
l/4
hr)
Monoclonal-Antibody Group
To
tal
Are
a u
nd
er t
he
C-P
epti
de
Res
po
nse
Cu
rve
(nm
ol/
l/4
hr)
Control Group
Large NIH Prevention Initiatives
• Immune Tolerance Network
• DPT-1 ===> TrialNet
• Autoimmunity Centers Excellence
• Autoimmunity Prevention Centers
Rewers-BDC
IDS Guidelines for Intervention TrialsIDS Guidelines for Intervention TrialsGreenbaum and Harrison:Diabetes 52:1059, 2003Greenbaum and Harrison:Diabetes 52:1059, 2003
• Diagnosis ADA criteria• Document: age,sex,pubertal, family history,glucose,
bicarb,ketoacidosis, weight loss, symptoms,HbA1c,islet autoab, insulin Rx, HLA
• Phase I >=18• GAD, IA-2, IAA(<2 wks), and if DM ICA C-peptide>=.2 nmol/L, early =
<12 weeks from diagnosis• >=2 year trials• Randomize, blind, mask, safety review, tight control, and continue
insulin• 2 hr. AUC C-Peptide with meal tolerance test, no AM insulin except
pump basal, fasting glucose 4-11.1 mmol/l• Measure islet autoAb other immune with HLA